University of Utah researchers found that one of the most widespread bacterial immune systems is switched on when a viral enzyme slices a host sensor protein, a trigger unlike anything seen in related antiviral pathways.

Bacteria have enemies of their own. Viruses called bacteriophages, or phages, infect them, hijack their machinery and burst them open. Over billions of years, bacteria have evolved an arsenal of immune systems to fight back, and biologists have spent the past decade cataloguing them.

One of the most common of those systems has kept a secret: nobody knew what tipped it off that an infection was under way. Researchers at University of Utah Health now report the answer in Science, and it turned out to be the opposite of what they expected. The bacterium does not detect the virus directly. It detects the damage the virus does to one of the bacterium’s own proteins.

“This is one of the most common forms of bacterial immunity, so when we finally figured it out, it was a total eureka moment,” said Sam Hobbs, an assistant professor of biochemistry at University of Utah Health and the study’s first author.

A self-destruct button

The system in question is called CBASS, and it is a drastic form of defense. Rather than trying to clear the infection, CBASS kills the infected bacterium outright, before the virus can finish replicating and spread to neighbouring cells.

In a colony of genetically identical bacteria, that trade can make sense. One cell dies, but its death denies the phage a factory and spares the cells around it. Biologists sometimes call this abortive infection, and several bacterial immune systems work the same way.

Because the response is lethal, the trigger has to be reliable. A sensor that fired at the wrong moment would kill a healthy cell for nothing. That made the question of what activates CBASS particularly interesting, and particularly hard to answer.

Bacteria carry a striking number of such systems, often clustered together in regions of the genome known as defense islands. Surveys of microbial genomes over the past decade have turned up dozens of distinct families, and CBASS is among the most widespread, found in a substantial fraction of sequenced bacteria.

Caught in the act

Related antiviral pathways tend to watch for viral genetic material, nucleic acids that look foreign or appear where they should not be. CBASS, the Utah team found, works differently.

The clue was an enzyme that some phages carry. “Certain kinds of phages have a protein called a protease, which degrades other proteins,” Hobbs said. Proteases are molecular scissors; phages use them during infection to process their own proteins and to dismantle the host’s.

The researchers discovered that the phage protease cuts a key sensor protein belonging to the bacterium, and that the act of cutting is itself the alarm.

“We found that the protease from the phage actually acts directly on the host protein, and that is the signal that turns on the whole signaling pathway,” Hobbs said.

It is a kind of booby trap. The bacterium leaves out a protein that the virus’s own tools will inevitably damage, and the damage sets off the response. A cell cannot easily be fooled by a decoy, because the trigger is an action only a genuine infection performs.

“This is a totally new mechanism for how these host proteins are activated,” Hobbs said. “I never would have guessed that this was the way it was going to work.”

An immune system older than animals

CBASS is more than a curiosity of microbiology. It is related to a signalling pathway in the human immune system, which means the basic design has been preserved since bacteria and the ancestors of animals parted ways.

“The fact that these systems are conserved between bacteria and humans suggests that they’ve been maintained in these different organisms for that entire evolutionary trajectory,” Hobbs said. “The cells are telling us that this is a really important pathway because they’ve maintained it for billions of years.”

That deep conservation is part of why bacterial immunity has become such a productive field. Bacteria divide in minutes rather than days, grow in enormous numbers and are easy to manipulate genetically, which makes them a fast testing ground for questions about how cells detect and respond to viruses.

“It’s incredibly fascinating, and it’s a cool window into what’s important in maintaining the ability to fight viruses,” Hobbs said.

The most famous example of this pipeline is CRISPR, a bacterial defense system against phages that became the basis of modern gene editing. Researchers studying other bacterial immune systems have since found molecules with echoes in human immunity.

Why it matters for phage therapy

There is also a practical motivation. Phages kill bacteria without harming human cells, which makes them appealing as a treatment for infections that resist conventional antibiotics. Doctors have used phage preparations for more than a century in some countries, and interest has surged as antibiotic resistance has spread.

The approach has a built-in obstacle, though. Bacteria are not passive targets. Their immune systems, including CBASS, can destroy an incoming phage or sacrifice the infected cell before the phage multiplies. A therapeutic phage that trips a defense system may never reach the numbers needed to clear an infection.

Knowing exactly what activates CBASS gives researchers something concrete to work with. In principle, phages used as medicines could be chosen or engineered so that they do not set off the trigger, or treatments could be designed to disable it.

The Utah work does not take that step. It identifies the mechanism, and the release reports no sample sizes or efficacy figures, because the study is about how the pathway is switched on rather than about treating an infection.

Still, the shift in understanding is substantial. For years, researchers assumed bacterial sensors looked for the virus itself. This one listens instead for the sound of the break-in.

The research was supported by the Pew Biomedical Scholars program, the Burroughs Wellcome Fund, the G. Harold and Leila Y. Mathers Foundation, the Cancer Research Institute, the Parker Institute for Cancer Immunotherapy, the Massachusetts Consortium on Pathogen Readiness and the National Institute of General Medical Sciences at the National Institutes of Health.

---

Notes

1. Hobbs, S., et al. “Phage proteases activate CBASS antiphage immunity.” Science, 2026. DOI: 10.1126/science.aeg3949.
2. University of Utah Health. “Research uncovers how bacteria fight viruses, opening the door to better virus-based antibiotics.” EurekAlert!, 1 October 2026. https://www.eurekalert.org/news-releases/1145696.